Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
GAITHERSBURG, Md., Nov. 02, 2016 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will host an Investor and Analyst update as part of its third quarter financial results conference call and webcast after the close of U.S. financial markets on Wednesday, November 9, 2016.
Management will host a conference call to discuss the quarterly financial results and provide an update on corporate activities. Please be sure to join the webcast in order to access the slide presentation.
Conference call details are as follows:
| Date: | Wednesday, November 9, 2016 |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
| Passcode: | 10126707 |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call replay:
| Dates: | Starting at 7:30 p.m. ET, August 9, 2016 until August 16, 2016 |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
| Passcode: | 10126707 |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000
